Olga Sala-Torra

Olga Sala-Torra

Auto-generated profile, based on publicly available information

Olga Sala-Torra

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
OSOlga Sala-Torra
Olga Sala-Torra
CHColleen Hanna
Colleen Hanna
MLMichael R. Loken
Michael R. Loken
MFMary E.D. Flowers
Mary E.D. Flowers
MMMichael Maris
Michael Maris
JRJerald P. Radich
Jerald P. Radich
Increasing the upper age limit for recipients of hematopoietic stem cell transplantation (HCT) naturally has also increased the age of the corresponding related donor population. Because aging is a risk factor for malignancies, the risk of transferring preexisting malignant or premalignant hemopoietic clones in the process of HCT might be expected to increase as well. Anecdotal clinical cases of malignancies derived from donor cells in patients undergoing HCT have been published since 1971. In this article, we report 12 new cases that fit 2 different categories: (1) cases in which clones with characteristics of lymphohemopoietic malignancies were transferred from the donors to the recipients and (2) cases in which the malignant clone evolved from healthy donor cells once transplanted into the recipient. Donors in the first group were significantly older than donors in the second group. A more systematic examination of the prevalence and biology of donor malignancies would merit study.

14 December 2006 in Blood
Verified
Journal Article
Open access
PDF file
OSOlga Sala-Torra
Olga Sala-Torra
HGHolly M. Gundacker
Holly M. Gundacker
DSDerek L. Stirewalt
Derek L. Stirewalt
PLPaula A. Ladne
Paula A. Ladne
EPEra L. Pogosova-Agadjanyan
Era L. Pogosova-Agadjanyan
JRJerald P. Radich
Jerald P. Radich
We compared the gene expression profile of adult acute lymphoblastic leukemia (ALL) to normal hematopoietic and non-ALL samples using oligonucleotide arrays. Connective tissue growth factor (CTGF) was the highest overexpressed gene in B-cell ALL compared with the other groups, and displayed heterogeneous expression, suggesting it might have prognostic relevance. CTGF expression was examined by quantitative reverse transcriptase–polymerase chain reaction (QRT-PCR) on 79 adult ALL specimens. CTGF expression levels were significantly increased in ALL cases with B-lineage (P < .001), unfavorable cytogenetics (P < .001), and blasts expressing CD34 (P < .001). In a multivariate proportional hazards model, higher CTGF expression levels corresponded to worsening of overall survival (OS; hazard ratio 1.36, for each 10-fold increase in expression; P = .019). Further studies are ongoing to confirm the prognostic value of CTGF expression in ALL and to investigate its role in normal and abnormal lymphocyte biology.

1 April 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
OTOlga Sala Torra
Olga Sala Torra
MOMegan Othus
Megan Othus
DWDavid W. Williamson
David W. Williamson
BWBrent Wood
Brent Wood
IKIlan Kirsch
Ilan Kirsch
JRJerald P. Radich
Jerald P. Radich
We used next-generation sequencing (NGS) of the immunoglobulin genes to evaluate residual disease in 153 specimens from 32 patients with adult B cell acute lymphoblastic leukemia enrolled in a single multicenter study. The sequencing results were compared with multiparameter flow cytometry (MFC) data in 66 specimens (25 patients) analyzed by both methods. There was a strong concordance (82%) between the methods in the qualitative determination of the presence of disease. However, in 17% of cases, leukemia was detected by sequencing but not by MFC. In 54 bone marrow (BM) and peripheral blood (PB) paired specimens, the burden of leukemia detected by NGS was lower in PB than in BM, although it was still detectable in 68% of the 28 paired specimens with positive BM. Lastly, patients without disease detected by NGS or MFC had a 5-year relapse free survival of > 80%. The results suggest that residual disease detection by immunoglobulin gene sequencing is an extremely sensitive technique and may identify patients that might benefit from transplantation. Moreover, the increased sensitivity of the method may allow frequent peripheral blood testing to supplement marrow sampling to measure disease response.

17 June 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
OSOlga Sala-Torra
Olga Sala-Torra
LBLan W. Beppu
Lan W. Beppu
FAFaduma A. Abukar
Faduma A. Abukar
JRJerald P. Radich
Jerald P. Radich
CYCecilia C. S. Yeung
Cecilia C. S. Yeung
Olga Sala-Torra, Lan W Beppu, Faduma A Abukar, Jerald P Radich, Cecilia CS Yeung; TTMV-RARA fusion as a recurrent cause of AML with APL characteristics, Blood A

2 June 2016 in Blood
Verified
Journal Article
Open access
PDF file
OTOlga Sala Torra
Olga Sala Torra
LBLan Beppu
Lan Beppu
JSJordan L. Smith
Jordan L. Smith
LWLinda Welden
Linda Welden
JGJasmina Georgievski
Jasmina Georgievski
JRJerald P. Radich
Jerald P. Radich

23 August 2021 in BMC Genomics
Verified
Journal Article
Open access
PDF file
SRShishir Reddy
Shishir Reddy
LHLing-Hong Hung
Ling-Hong Hung
OSOlga Sala-Torra
Olga Sala-Torra
JRJerald P. Radich
Jerald P. Radich
CYCecilia Cs Yeung
Cecilia Cs Yeung
KYKa Yee Yeung
Ka Yee Yeung
Background: Long-read sequencing has great promise in enabling portable, rapid molecular-assisted cancer diagnoses. A key challenge in democratizing long-read sequencing technology in the biomedical and clinical community is the lack of graphical bioinformatics software tools which can efficiently process the raw nanopore reads, support graphical output and interactive visualizations for interpretations of results. Another obstacle is that high performance software tools for long-read sequencing data analyses often leverage graphics processing units (GPU), which is challenging and time-consuming to configure, especially on the cloud. Results: We present a graphical cloud-enabled workflow for fast, interactive analysis of nanopore sequencing data using GPUs. Users customize parameters, monitor execution and visualize results through an accessible graphical interface. The workflow and its components are completely containerized to ensure reproducibility and facilitate installation of the GPU-enabled software. We also provide an Amazon Machine Image (AMI) with all software and drivers pre-installed for GPU computing on the cloud. Most importantly, we demonstrate the potential of applying our software tools to reduce the turnaround time of cancer diagnostics by generating blood cancer (NB4, K562, ME1, 238 MV4;11) cell line Nanopore data using the Flongle adapter. We observe a 29x speedup and a 93x reduction in costs for the rate-limiting basecalling step in the analysis of blood cancer cell line data. Conclusions: Our interactive and efficient software tools will make analyses of Nanopore data using GPU and cloud computing accessible to biomedical and clinical scientists, thus facilitating the adoption of cost effective, fast, portable and real-time long-read sequencing.